Insulin glargine's main metabolic effect as metabolite M1

October 25, 2012
Insulin glargine's main metabolic effect as metabolite M1
For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration is in the form of its metabolite M1, according to a study published online Oct. 18 in Diabetes Care.

(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration is in the form of its metabolite M1, according to a study published online Oct. 18 in Diabetes Care.

To examine the concentration of plasma and its metabolites after subcutaneous dosing, Paola Lucidi, M.D., Ph.D., from the University of Perugia in Italy, and colleagues performed a 32-hour euglycemic glucose clamp study (0.4 units/kg glargine after one week of daily glargine administration) in nine patients with . A -tandem mass spectrometry assay was used to measure glargine, M1, and M2.

The researchers found that, in five out of nine patients, glargine was detected at negligible concentrations and at few time points. M1 exhibited the same pattern as traditional radioimmunoassay-measured plasma insulin and was detected in all patients. There was no detection of M2 at all.

"In conclusion, after subcutaneous injection of a therapeutic dose in glargine-treated type 2 diabetic subjects, glargine is only transiently, and at minimal concentration, detectable in plasma, whereas its metabolite M1 accounts for most (>90 percent) of the plasma insulin concentration," the authors write. "Thus, in vivo, glargine does not exert its long-acting directly as glargine but predominantly via its main metabolite M1."

Several authors disclosed financial ties to pharmaceutical companies, including sanofi-aventis, which funded the study.

Explore further: Experimental insulin drug prevents low blood sugar

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Experimental insulin drug prevents low blood sugar

June 25, 2012
An experimental insulin drug prevented low blood sugar among diabetic patients more often than a popular drug on the market, a new study finds. The results will be presented at The Endocrine Society's 94th Annual Meeting ...

The effect of insulin glargine and fish oil supplements on atherosclerosis progression

August 27, 2012
A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared ...

Recommended for you

In a nutshell: Walnuts activate brain region involved in appetite control

August 17, 2017
Packed with nutrients linked to better health, walnuts are also thought to discourage overeating by promoting feelings of fullness. Now, in a new brain imaging study, researchers at Beth Israel Deaconess Medical Center (BIDMC) ...

Smart mat detects early warning signs of foot ulcers

August 16, 2017
While completing his residency in anesthesiology at Massachusetts General Hospital in the mid-2000s, Jon Bloom saw his fair share of foot amputations among patients with diabetes. The culprit: infected foot ulcers.

The best place to treat type 1 diabetes might be just under your skin

August 14, 2017
A group of U of T researchers have demonstrated that the space under our skin might be an optimal location to treat type 1 diabetes (T1D).

New measure of insulin-making cells could gauge diabetes progression, treatment

August 10, 2017
Researchers at the University of Wisconsin-Madison have developed a new measurement for the volume and activity of beta cells, the source of the sugar-regulating hormone insulin.

Pioneering immunotherapy shows promise in type 1 diabetes

August 9, 2017
It may be possible to 'retrain' the immune system to slow the progression of type 1 diabetes, according to results of a clinical trial published today in the journal Science Translational Medicine.

Online team-based game helps patients with diabetes lower blood glucose

August 8, 2017
Researchers from Brigham and Women's Hospital and the Veterans Affairs Boston Healthcare System have found that an online, team-based game designed to teach patients about diabetes self-management had a sustained and meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.